This cascade of events culminates in improved obesity and glucose homeostasis, making irisin a promising therapeutic target for metabolic disorders and diseases amenable to physical exercise interventions [7]. The gene discussed is FNDC5; the disease is obesity due to melanocortin 4 receptor deficiency.